63 mm for women and 18.51 mm for men in elderly communities in the Central-West Region of Brazil.

The APMT can be used for the diagnosis of sarcopenia. The optimal cutoff points for APMT are 17.63 mm for women and 18.51 mm for men in elderly communities in the Central-West Region of Brazil.

Skipping breakfast prolongs the fasting state initiated after the last meal consumed the previous day and can have negative effects on muscle protein balance. The aim of this crossover trial was to examine the effects of skipping breakfast before a single bout of resistance exercise (RE) on muscle protein breakdown (MPB), as assessed using the urinary 3-methylhistidine/creatinine ratio (3-MH/Cr).

Thirteen healthy young men, who habitually consumed breakfast (21.8 ± 1.1 y of age), were assigned to eating breakfast (EB) and skipping breakfast (SB) conditions. Participants consumed meat-free diets throughout the 5-d experiment. On day 5, individuals in the EB group consumed breakfast (497 kcal) 2.5 h before RE (75% repetition maximum), whereas those in the SB group consumed the same meal after dinner.

In the two-way analysis of variance, significant interactions were observed with blood insulin and free fatty acid levels, and the 3-MH/Cr ratio (P < 0.05). We confirmed a significantly greater decrease in the insulin level pre-RE (P < 0.001; d=3.281), and increases in the free fatty acid level pre-RE (P < 0.001; d=1.437) and post-RE (P = 0.013; d=0.811) and the 3-MH/Cr ratio 6 (P < 0.001; d=0.878) and 8 h (P < 0.001; d=0.634) post-RE in the SB condition than in the EB condition.

Eating breakfast before RE can be beneficial for MPB suppression. The importance of breakfast consumption in terms of positive muscle protein balance is emphasized on sports fields.

Eating breakfast before RE can be beneficial for MPB suppression. The importance of breakfast consumption in terms of positive muscle protein balance is emphasized on sports fields.

This study aimed to investigate the potential of using changes in the plasma levels of trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, as a biomarker in early Parkinson’s disease (PD).

Plasma TMAO levels were measured in 85 patients with drug-naïve early stage PD and 20 healthy controls. A linear mixed model was used to assess longitudinal changes in levodopa-equivalent dose (LED) during follow-up (>2 y) in three tertile PD groups according to plasma TMAO levels. Additionally, a Cox regression analysis was performed to assess the effect of plasma TMAO levels on dementia conversion.

Plasma TMAO levels of patients with PD were lower than those of healthy controls. Lifirafenib A linear mixed model demonstrated that patients with PD and lower levels of TMAO (<4.75 μmol/L; i.e., lowest tertile group) exhibited faster increases in LED over time. The Cox regression model did not reveal that plasma TMAO level was associated with the risk for dementia conversion (P = 0.488). However, when we divided patients with PD into two subgroups according to bet cutoff TMAO level to maximize the log-rank statistics, the PD group with a low plasma TMAO level (<6.92 μmol/L) had a higher risk (with borderline statistical significance) for PD-dementia conversion than the group with a high TMAO level (hazard ratio 7.565; 95% confidence interval, 1.004-57.019; P = 0.050).

The results demonstrate that lower baseline plasma TMAO levels are associated with faster increases in LED and tend to increase the risk for PD-dementia conversion, suggesting the prognostic implications of TMAO in early stage PD.

The results demonstrate that lower baseline plasma TMAO levels are associated with faster increases in LED and tend to increase the risk for PD-dementia conversion, suggesting the prognostic implications of TMAO in early stage PD.

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting a significant proportion of the general population. Recently, randomized clinical trials have been conducted examining the efficacy of silymarin in individuals with NAFLD, with conflicting results. The aim of this meta-analysis was to evaluate the efficacy of silymarin in the treatment of NAFLD by examining changes in liver biochemistry, body mass index, and liver histology.

We searched major electronic databases PubMed/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, as well as gray-literature sources, up to June 2020 for randomized clinical trials examining the efficacy of treatment with silymarin in individuals with NAFLD compared to placebo. The primary outcomes were changes in the mean values of transaminases (alanine aminotransferase and aspartate aminotransferase). Secondary outcomes included changes in body mass index and liver histology. Quality analysis was performed with the risk-of-bias tool 2tudies should be carried out to examine whether this reduction in transaminase levels corresponds to histologic improvement.

This study aimed to analyze the expression pattern of microRNAs (miRNAs) in white blood cells (WBC) in response to two different energy-restricted diets in patients with metabolic syndrome in the Metabolic Syndrome Reduction in Navarra-Spain (RESMENA) study.

A subsample of 24 patients with metabolic syndrome features from the randomized, prospective, parallel-designed RESMENA study was selected for this analysis. The RESMENA study consisted of two dietary strategies with a 30% energy restriction RESMENA (high meal frequency and high adherence to the Mediterranean diet) and control (based on recommendations from the American Heart Association) groups. Anthropometric and biochemical parameters as well as miRNA expression in WBC by miRNA-seq were measured before and after 8 wk of intervention.

A total of 49 miRNAs were differentially expressed after 8 wk of dietary intervention, 35 from the American Heart Association and 14 from the RESMENA diet. MiR-410, miR-637, miR-214, and miR-190 evidenced the most sithese miRNAs might be directly or indirectly involved in the effects of weight-loss diets with different foods and macronutrient composition, and participate in the regulation of metabolic diseases.